Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Non Operating Income (2023 - 2025)

Zenas BioPharma has reported Non Operating Income over the past 3 years, most recently at -$7.2 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$7.2 million for Q4 2025, down 58.59% from a year ago — trailing twelve months through Dec 2025 was $417000.0 (up 106.44% YoY), and the annual figure for FY2025 was $417000.0, up 106.44%.
  • Non Operating Income for Q4 2025 was -$7.2 million at Zenas BioPharma, down from $1.1 million in the prior quarter.
  • Over the last five years, Non Operating Income for ZBIO hit a ceiling of $3.6 million in Q1 2025 and a floor of -$7.2 million in Q4 2025.
  • Median Non Operating Income over the past 3 years was $937000.0 (2023), compared with a mean of $139600.0.
  • Peak annual rise in Non Operating Income hit 14962.5% in 2024, while the deepest fall reached 670.62% in 2024.
  • Zenas BioPharma's Non Operating Income stood at $793000.0 in 2023, then plummeted by 670.62% to -$4.5 million in 2024, then tumbled by 58.59% to -$7.2 million in 2025.
  • The last three reported values for Non Operating Income were -$7.2 million (Q4 2025), $1.1 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.